
TREATMENTS
Exploring new frontiers for the treatment of Lyme Disease
TREATMENTS
Exploring new frontiers for the treatment of Lyme Disease
17+ Years of using patented and proven stem cell treatments for Lyme Disease
Lyme is a condition caused by bacterium Borrelia burgdorferi. The black-legged tick, also known as the deer tick, carries the bacteria that causes Lyme infection and is solely responsible for transmitting the disease to humans. Typical symptoms include fever, headache, fatigue and a characteristic skin rash called erythema migrans - a “bulls-eye” rash, which is a sign that bacteria are multiplying in the bloodstream. The disease manifests itself as a multisystem inflammatory disease that affects the skin in its early, localized stage, and spreads to the joints, nervous system and, to a lesser extent, other organ systems in its later, disseminated stages.
If diagnosed early, antibiotics can nip the infection in the bud. Rarely does the disease caused any permanent damage. With stem cell technology, new cells are administered in the body that are capable of regenerating 200+ cell types that help in repair and regeneration of organ and its function and reversal of symptoms associated with the condition.
Once infused, stem cells are known to be differentiating into cells of different organs to repair the damage caused due to the disease with respect to infection, reduced immunity, systemic damage and impairments, if any. Patients have shown improvement post the treatment and antibiotic regimen.
At Nutech MediWorld, the patients’ clinical condition is assessed for safety and efficacy of the treatment using conventional systems to check their eligibility for stem cell treatment for Lyme Disease.
We also conduct an additional round of thorough assessment using our patented NFS (Nutech Functional System) protocols whereby condition-based sets of parameters have been pre-devised for a finer assessment of the patient’s condition (and progress).
After evaluating the specific patient’s condition, a unique/bespoke treatment protocol is decided. This protocol is based on our proprietary stem cell platform, Reostem®.
The patient’s progress is monitored on a weekly basis to further optimise treatment protocols depending on the patient’s response.
At the end of the treatment, a complete assessment is done to track progress from when the patient came into where he/she has reached now. If required, a follow-up protocol is recommended.
At Nutech MediWorld, we follow an evidence-based, non-invasive, multi-disciplinary approach using Stem Cell Treatment & supporting therapies to improve the condition and overall quality of life for Lyme Disease patients. Each treatment protocol comprises of the use of our patented technology, customized to suit the condition of the individual patient.
At Nutech MediWorld, we follow an evidence-based, non-invasive, multi-disciplinary approach using Stem Cell Treatment & supporting therapies to improve the condition and overall quality of life for Lyme Disease patients. Each treatment protocol comprises of the use of our patented technology, customized to suit the condition of the individual patient.
At Nutech MediWorld, the patients’ clinical condition is assessed for safety and efficacy of the treatment using conventional systems to check their eligibility for stem cell treatment for Lyme Disease.
We also conduct an additional round of thorough assessment using our patented NFS (Nutech Functional System) protocols whereby condition-based sets of parameters have been pre-devised for a finer assessment of the patient’s condition (and progress).
After evaluating the specific patient’s condition, a unique/bespoke treatment protocol is decided. This protocol is based on our proprietary stem cell platform, Reostem®.
The patient’s progress is monitored on a weekly basis to further optimise treatment protocols depending on the patient’s response.
At the end of the treatment, a complete assessment is done to track progress from when the patient came into where he/she has reached now. If required, a follow-up protocol is recommended.
We use SCT-N® and SCT-NX® products, based on a proprietary stem cell platform, ReoStem®, which comprises of a unique, replicable, clinical-stage technology for the generation and clinical application of allogenic stem cells.
Nutech Mediworld’s regenerative medicine products are universally applicable: they do not require tissue-matching or the co-administration of immunosuppressive drugs.
There is no evidence of teratoma generation or tumorigenesis associated with SCT-N® or SCT-NX® use in over 17 years of clinical practice across thousands of patients.
The unique cell culture methodology allows scalability of cell expansion and production.